NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 29, 2017

Primary Completion Date

April 1, 2019

Study Completion Date

September 25, 2019

Conditions

Solid Tumor

Interventions

DRUG

NLG802

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor

Trial Locations (3)

University of Florida, Gainesville

Washington University School of Medicine, St Louis

University of New Mexico Comprehensive Cancer Center, Albuquerque